From our list 18 new health tech startups in Europe worth knowing (2026)
Aptadir Therapeutics is developing a new class of RNA inhibitors that silence defective genes, starting with Fragile X Syndrome, and is at the preclinical stage. Founded in 2023 by Annalisa Di Ruscio, Daniel Tenen, Vittorio de Franciscis, Giovanni Amabile and Marcin Kortylewski, it announced a 45 million dollar seed round led by 4BIO Capital on 29 September 2026. Website: aptadir.com. Sources: Tech.eu, BeBeez. Also in our list: New startups in Milan (2026).
From our list 10 new startups in Milan worth knowing (2026)
Aptadir Therapeutics is developing a new class of RNA inhibitors that silence defective genes, starting with Fragile X Syndrome, and is at the preclinical stage. Founded in 2023 by Annalisa Di Ruscio, Daniel Tenen, Vittorio de Franciscis, Giovanni Amabile and Marcin Kortylewski, it announced a 45 million dollar seed round led by 4BIO Capital on 29 September 2026. Website: aptadir.com. Sources: Tech.eu, BeBeez.
Questions about Aptadir Therapeutics
What does Aptadir Therapeutics do?
Aptadir Therapeutics: RNA medicines for hard-to-treat genetic conditions.
Where is Aptadir Therapeutics based?
Aptadir Therapeutics is based in Milan, Italy.
Where can I read more about Aptadir Therapeutics?
Aptadir Therapeutics is in our list 18 new health tech startups in Europe worth knowing (2026): https://meetnewbrands.com/articles/new-health-tech-startups-in-europe-2026